Get started
Author

Patrick J. McCann

Observed name: Patrick McCann
ORCID: 0000-0002-1836-4617
Observed ORCID: 0000-0002-1836-4617
OpenAlex ID: A5030978613
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators
2023 · Aleksandar Obradovic, Casey Ager, et al. · Cancer Cell · 66
PDF
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al. · Clinical Cancer Research · 33
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer
2024 · Casey R. Ager, Aleksandar Obradovic, et al. · medRxiv · 7
Phase II Study of an Androgen Receptor Pathway Inhibitor + Atezolizumab + Gonadotropin-Releasing Hormone Analog and Stereotactic Body Radiotherapy in Hormone-Sensitive Metastatic Prostate Cancer
2026 · Matthew Dallos, Mark Stein, et al. · JCO oncology advances.
PDF
Abstract 7419: Comprehensive profiling of primary and metastatic prostate tumors reveals distinct tumor and fibroblast cell states associated with androgen resistance
2026 · Aleksandar Obradovic, Kwangmin Yoo, et al. · Cancer Research
Supplementary Figure S2 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Supplementary Table S1 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Data from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Supplementary Table S2 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Supplementary Figure S1 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Supplementary Table S3 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Supplementary Figure S3 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2026 · Deaglan McHugh, Matthew Dallos, et al.
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2025 · Deaglan McHugh, Matthew Dallos, et al. · Clinical Cancer Research
PDF
433 Tumor and circulating immune dynamics in prostate cancer treated with PD-L1 blockade, radiation and hormonal therapy: a multiparametric translational analysis from the SAABR trial
2025 · Matthew Dallos, Patrick McCann, et al. · Regular and Young Investigator Award Abstracts
PDF
Data from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Supplemental Figure S2 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Supplemental Figure S3 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Supplemental Figure S1 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Supplemental Figure S6 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Supplemental Figure S5 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Supplemental Figure S4 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
2024 · Matthew C. Dallos, Aleksandar Z. Obradovic, et al.
Works count: 21
Citation count: 106
H-index: 3
I10-index: 2
Year
Topic
Type